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The following section should be added after the ‘‘Coagulation pathway submodel’’ section of our article:Clarification of the relation of the biochemical reactions submodel to previous models
The model from Hockin et al. (14) is an extension of one of the first computational models predicting thrombin production of
the TF-initiated procoagulant pathway in vitro developed by Jones and Mann (12) by including stoichiometric inhibitor
systems such as the tissue factor pathway inhibitor-mediated inactivation of tissue factor and active factor VII complex
and its product complexes. The ordinary differential equations (ODEs) model in Hockin et al. (14) includes an intermediate
stage in the activation of prothrombin to thrombin: meizothrombin as a part of the reaction network that is not represented in
the ODE models in Kuharsky and Fogelson (17) and Fogelson and Tania (26). Meizothrombin is an intermediate product
generated by one pathway for the conversion of prothrombin to thrombin. In Edwin et al. (31), experimental data clearly
demonstrates the importance of meizothrombin and, therefore, it is important to consider its significance when modeling
the coagulation reactions in the blood. The model in Hockin et al. (14) captured most experimentally observable parameters
and accurately described pathology that results in enhanced or deficient thrombin generation (14).
The general idea of including membrane-phase reactions in coagulation models was introduced and demonstrated in
Kuharsky and Fogelson (17) using the ODEs model (see reference to (17) in ‘‘Biological and modeling background’’ section).
In our study, we extended the specific model of the coagulation network from Hockin et al. (14), which is different from the
one described in Kuharsky and Fogelson (17), by incorporating both solution-phase and membrane-phase reactions with
concentrations of membrane-binding sites as described in Kuharsky and Fogelson (17) and by using new assumptions,
components, and submodel implementation to generate a multiscale model predicting thrombus development both in time
and space.
As stated previously in our article, the main novelty of our modeling approach is in describing in detail production of
thrombin on the membrane of each individual platelet (modeled as an extended object with a finite volume and stochastically
fluctuating membrane by the CPM) and in coupling the complete set of model components at different space and time scales
into a multiscale model. Each platelet or other blood cell is carried by blood flow modeled by a detailed fluid dynamics PDEs
model (Navier-Stokes equation and Darcy’s law equation) and may be incorporated into a thrombus. We focus on modeling
space structure of thrombi developing under different conditions, both in time and space, using PDEs and ODEs coupled with
a cell-based stochastic discrete model (CPM) for blood cells (see Fig. 1) and comparing simulations with experimental data
obtained by our group. Most of the components in our model are spatially dependent, and they are described by PDEs and
stochastic discrete dynamical systems (CPMs) compared to ODEs in the models from Hockin et al. (14), Kuharsky and
Fogelson (17), and Fogelson and Tania (26). Therefore, behavior of all components in the system of equations is different
compared to Hockin et al. (14), Kuharsky and Fogelson (17), and Fogelson and Tania (26) since we take into account
both time and space variables and because all components of the model are linked together through stochastic CPM. The
ODE model in Hockin et al. (14) includes meizothrombin as a part of the reaction network. We also specifically model
its production by introducing two separate equations (4.25) and (4.45), one for meizothrombin in the plasma flow and
the other for meizothrombin on platelet membranes. Namely, the volume concentration of thrombin, p2 is a sum of binding
sites for platelet-bound thrombin (IIa), prothrombin (II), and meizothrombin (mIIa), and their complex
p2 ¼ ½IIma  þ ½IIm þ ½mIIma þ½Xa: Va: IIm and the volume concentration emtot2 is a sum of active platelet-bound thrombin
and meizothrombin emtot2 ¼ ½IIma  þ ½mIIma  (see the Supporting Material).
The concept that spatial separation between the site of coagulation factor activation and site of activity affects the
dynamics of thrombus development was suggested by Roberts et al. (32) in a cell-based model of coagulation. In this model,
coagulation initiation reactions (TF-FVII activation of FX) occurred on monocytes in blood or fibroblasts in the injured vessel
wall whereas the propagation reactions generating a large burst of thrombin occurred on activated platelets. The concept
of spatial separation was also raised in Geisen et al. (33) and Hathcock et al. (34), which described the importance of
blood-borne tissue factor for thrombus development. Geisen et al. (33) suggested that ‘‘This phenomenon would clearly
favor thrombus propagation because factors IXa and Xa, both initial products of the TF pathway, would be generated on
TF-containing microvesicles at the platelet surface, thereby reducing the distance they must diffuse from the source of TF
to the platelet surface.’’ Later results in Hathcock et al. (34) suggest that thrombus growth would be severely limited if
Correction 2385activation of FX from flowing blood required diffusion through the thrombus to TF-FVIIa complexes on cells within the
vessel wall. This work from the Nemerson laboratory supported the now widely accepted contention of the cell-based model
of coagulation that the physical separation between the sites of coagulation zymogen activation and the sites of coagulation
factor activity will affect the dynamics of coagulation factor interactions. In addition to the issue of the FVII-TF activation of
FIX and FX, this concern also applies to the separation of sites for PC activation, which requires thrombomodulin (Tm) on
quiescent endothelialial cells and sites of APC activity (to inactivate FV and and FVIII) in a developing thrombus.
The protein C related coagulation network component in our multistage model, as indicated in the ‘‘Protein C pathway
component’’ subsection, is similar to the one described in Fogelson and Tania (26) and incorporates lateral diffusion of
PC from sites outside the plane as introduced in Fogelson and Tania (26), which raised the issue of spatial separation of
the site of PC activation and APC activity. The model described in our article extends the approach of Fogelson and Tania
(26) in several important ways:
1. We model thrombin and thrombomodulin concentration on endothelial cells ½IIECa , active protein C generated on the endo-
thelial cell surface [APCEC], and active protein C [APC] in time and space by partial differential equations (4.46), (4.49)
and (4.50).
2. Moreover, reactions of complexes of thrombomodulin-thrombin and thrombomodulin-thrombin-protein C, which are
modeled by ordinary differential equations (4.47) and (4.48), are coupled to the rest of the reaction network through
stochastic CPM. As a result, the model in Fogelson and Tania (26) and the one described in our article behave in a different
way. All reactions in Fogelson and Tania (26) are modeled by ordinary differential equations, which means that the spatial
variation of thrombin on endothelial cells, APC on endothelial cells, and APC are not included in the Fogelson and Tania
model (26).
3. Transport of a chemical is modeled in a different way. Namely, in the model deacribed in our article, the velocity of chem-
ical convection depends on time and on the size and structure of the growing thrombus.
The first paragraph of ‘‘Coagulation pathway submodel’’ section should read:
We extend the model of Hockin et al. (14) by including in the model both solution-phase and membrane-phase reactions
with concentrations of membrane-binding sites being limited and treated as control variables. (For detailed information on
composition of our biochemical submodel and its relation to the previous models, see the new section ‘‘clarification of the
relation of the biochemical reactions submodel to previous models’’.)
On page 1726, the fourth paragraph in the 2nd column should start with:
Note that although some notations in our model coincide with those in Kuharsky and Fogelson (17) and Fogelson and Tania
(26), our variables p2 and e
mtot
2 include additional terms for meizothrombin that were not considered in Kuharsky and
Fogelson (17) (see the ‘‘Relation of biochemical reactions submodel to previous models’’ section and the Supporting
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